Boule Diagnostics (BOUL) Q2 2024 earnings summary

Executive summary

• Q2 2024 net sales were SEK 137 million, down 2.5% year-over-year, with organic growth at -3.6% and currency impact +1.1%.

• Adjusted EBIT improved 13.8% to SEK 9.9 million, with adjusted operating margin at 7.2%; non-recurring restructuring and tax costs reduced reported EBIT to SEK 1.4 million.

• Strong cash flow from operating activities at SEK 13.8 million, up from SEK 3.4 million last year; available liquidity at quarter-end was SEK 82 million.

• Organizational restructuring in Q2 reduced headcount by eight, yielding annual gross savings of SEK 8 million.

• Strategic priorities include margin expansion, disciplined execution, organic investments, and portfolio development.

Financial highlights

• Adjusted gross profit was SEK 59.8 million, nearly flat year-over-year; gross margin improved to 43.6%.

• Adjusted operating expenses decreased to SEK 49.6 million from SEK 52.2 million.

• Earnings per share was SEK -0.04, down from 0.11 SEK.

• Net financial items improved to -SEK 2.6 million from -SEK 3.5 million.

• Cash flow from operations: SEK 13.8 million; net cash position: SEK -1.2 million.

Outlook and guidance

• Focus remains on cost optimization, structural cost reductions, and margin expansion.

• Strategic investments in technology, OEM consumables, and veterinary channel expansion to drive future growth.

• India license manufacturing for M20 device on track for Q4 2024; BM950 performance evaluation set for H2 2024.

• Long-term targets: operating margin >15%, sales growth >10%, net debt/EBIT <3x.

• No specific forward-looking statements or forecasts provided for the second half of the year.